


January 22, 2026



BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company on January 22, 2026 approved the appointment of Ms. Jill Mary De Simone (DIN:11483134) as Additional Director (Non-Executive Independent Director), subject to the approval of shareholders, for a term of three years effective from January 22, 2026 to January 21, 2029 (both days inclusive).

In terms of NSE circular NSE/CML/2018/24 dated June 20, 2018 and BSE circular LIST/COMP/14/2018-19 dated June 20, 2018, we hereby affirm that Ms. Jill Mary De Simone is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is mentioned in "Annexure-1".

The above information is being made available on the website of the Company <https://www.indegene.com/>.

This is for your information and records.

Yours Sincerely,
For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary & Compliance Officer



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

S. No.	Particulars	Details
1.	Name of Director	Ms. Jill Mary De Simone (DIN:11483134)
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Ms. Jill Mary De Simone as Additional Director (Non-Executive Independent Director), for a term of 3 years, subject to approval of the shareholders.
3.	Date of appointment, re-appointment, cessation and terms of appointment	January 22, 2026 Term: For a term of 3 years with effect from January 22, 2026 to January 21, 2029 (both days inclusive).
4.	Brief Profile (In case of appointment)	Ms. Simone is an accomplished biopharmaceutical executive and board director with extensive experience in driving growth, innovation, and governance across global healthcare organizations. A former President of U.S. Oncology at Merck, her career spans leadership roles at Merck, Teva, and Bristol Myers Squibb, where she managed full P&L responsibilities and launched transformative therapies in oncology, HIV, women's health, and general medicine. Currently, she advises preclinical and early-stage companies on commercialization and leadership transitions, serves on boards of public and private life sciences companies, and chairs advisory boards focused on AI in healthcare. Renowned for her strategic acumen, authentic leadership, and commitment to purpose-driven cultures, she brings deep industry expertise and a passion for mentoring leaders and shaping governance.
5.	Disclosure of relationship between directors (In case of appointment)	Not related to any Director of the Company.